Biotech trends in COVID era: the pharmaphorum podcast
In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.
Drawing on his experience with companies such as Silence Therapeutics, Akari Therapeutics, Bionor Pharma and Zealand Pharma, David picked out some of the key biotech trends for the current era of COVID-19.
These included the use of big data and artificial intelligence in drug development, with a focus on hard-to-treat, neurodegenerative diseases.
He also spoke about Pharnext’s progress to date in its mission to develop novel therapeutics for orphan and common neurodegenerative diseases, such as Charcot-Marie-Tooth Type 1A – an inherited neurological disorder that affects the peripheral nerves.
You can listen to episode 26 of the pharmaphorum podcast in the player below, download the episode to your computer or find it – and subscribe to the rest of the series in iTunes, Spotify, acast, Stitcher and Podbean.
